Page results
-
The North Central London Integrated Care System (NCL ICS) has new services and staff training to support patients with inherited red cell disorders, including Sickle Cell and Thalassaemia, living in Barnet, Camden, Enfield, Haringey and Islington.
-
The North Central London Integrated Care System (NCL ICS) has new services and staff training to support patients with inherited red cell disorders, including Sickle Cell and Thalassaemia, living in Barnet, Camden, Enfield, Haringey and Islington.
-
UCLH has recruited the first patient to a global study of a new drug in early development, called NI0752, which is thought to reduce the production of a protein in the brain called tau.
-
This information is for patients receiving steroids for immunotherapy toxicity.
-
This page is for cancer patients receiving immunotherapy treatment.
-
Participants reacted quicker and made fewer errors during menstruation, despite believing their performance would be worse, according to new research from UCL and the Institute of Sport, Exercise & Health (ISEH).
-
An immunotherapy drug given before surgery instead of chemotherapy meant that significantly more patients with a certain genetic profile were cancer free after surgery, according to clinical trial results presented by researchers at UCL and UCLH.
-
The Sickle Cell Society (SCS) and the UK Thalassaemia Society (UKTS) have worked in partnership with the NHS sickle cell and thalassaemia (SCT) screening programme to engage with communities less likely to access health information through usual NHS channels. The societies provide feedback from people that share the same population background or have experience of the condition and to feed into the programme updates and improvements.
-
Education and training videos for Red Cell Network patients
-
Information for service users about the RESPOND service for refugees and asylum seekers.
File results
-
FOI/2021/0715 - Urothelial cancer treatment
-
FOI/2021/0716 - COVID-19 deaths
-
FOI/2021/0721 - Maternity units within your trust
-
FOI/2021/0723 - Covid 19 deaths
-
FOI/2021/0730 - Treatment with Ofatumumab
-
FOI/2021/0736 - Prehabilitation
-
FOI/2021/0737 - Health information systems
-
FOI/2021/0710 - Patient safety incidents resulting in severe harm or death
-
FOI/2021/0732 - Policy for maternity partners
-
FOI/2021/0734 - Sexual harassment against catering staff